Brentuximab a novel antibody therapy: real‐world use confirms efficacy and tolerability for CD30‐positive cutaneous lymphoma

Engelina, S.; Saggu, Manpreet Kaur; Yoo, Jung‐Wan; Shah, Farida; Stevens, Annette; Irwin, Clive; Chaganti, Sridhar; Scarisbrick, Julia

doi:10.1111/bjd.18535

Cited by 14 publications

(21 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BV was an effective and safe treatment in our patient with CD30‐postive LCT PMF. Peripheral neuropathy was the only side effect of BV treatment in our patient, as previously reported (Alpdogan et al, ; Engelina et al, ).…”

Section: Discussionsupporting

confidence: 89%

“…In our patient, all available treatment modalities were used. Lack of effect and contraindications of conventional treatment made that BV became the treatment of choice (Alpdogan et al, ; Duvic et al, ; Engelina et al, ; Virmani et al, ).…”

Section: Discussionmentioning

confidence: 99%

“…BV is an ideal treatment for CD30‐expressing lymphomas and control of life‐threatening complications (Alpdogan et al, ; Duvic et al, ; Engelina et al, ; Virmani et al, ). BV is usually well‐tolerated, but some patients may develop sensory neuropathy (Duvic et al, ; Engelina et al, ). For MF, BV dose is 1.8 mg/kg, given iv, every 3 weeks, for up to 16 cycles (Prince et al, ; Younes et al, ).…”

Section: Discussionmentioning

confidence: 99%

“…Overall response rate, lasting at least 4 months, was significantly higher in BV group (56.3%) than in group treated by MTX or bexarotene (12.5%) (Prince et al, ). One study reports that the total number of BV therapies varied between patients, ranging from 4 to 16 (Engelina et al, ).…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Poikilodermatous mycosis fungoides with CD30‐positive large cell transformation successfully treated by brentuximab vedotin

Popadić

Lekić

Tanasilovic

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

We present a patient with a 33-year history of poikilodermatous mycosis fungoides (MF) who subsequently developed CD30-positive large cell transformation. After 6 years of conventional MF treatment, side effects of therapy and/or concomitant diseases prevented the previously applied treatment modalities. The CD30-directed antibody-cytotoxic drug conjugate (brentuximab vedotin) was introduced and followed by quick and excellent therapeutic response. K E Y W O R D S brentuximab vedotin, CD30-positive large cell transformation, mycosis fungoides

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Poikilodermatous mycosis fungoides with CD30‐positive large cell transformation successfully treated by brentuximab vedotin

Popadić

Lekić

Tanasilovic

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Based on these data, brentuximab vedotin was approved by the FDA in 2017 for the treatment of CD30+ MF and pcALCL following more than one prior systemic therapy (Adcetris Prescribing Information) 41 and by the EMA in 2018 for CD30+ CTCL (not including patients with SS) following more than one prior systemic therapy (Adcetris Product Information), 23 but it can only be administered for a maximum of 16 infusions. Early reports of real‐world data of brentuximab vedotin have shown similar results in CD30+ CTCL 101 …”

Section: Advanced Diseasementioning

confidence: 59%

The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T‐cell lymphoma

2020

Self Cite

View full text Add to dashboard Cite

Summary Cutaneous T‐cell lymphomas (CTCLs) have a chronic, relapsing course, and the most common subtypes are mycosis fungoides and Sézary syndrome. The disease causes visible skin alterations and can also cause alopecia, pruritus and pain, all of which can impact patients’ health‐related quality of life (HRQoL). The goal of treatment is to reduce symptoms and prevent disease progression. However, treatment recommendations are often based on low levels of evidence due to the lack of well‐designed randomised clinical trials and treatment guidelines, and approved drugs vary considerably across different countries and regions. Currently, available treatments rarely lead to durable remissions and eventually become less effective, meaning patients often require multiple therapy changes. Skin‐directed therapies (SDTs) are first‐line treatments for early‐stage CTCL, whereas systemic therapies may be needed for early‐stage disease that does not respond to SDT or for advanced‐stage disease. However, patients can experience significant side‐effects with these treatments or may be unable to tolerate them. Hence, there is an unmet need for effective therapies with good safety profiles for the treatment of early‐ and late‐stage CTCL. Here, we review current treatment guidelines, investigational and approved treatments, the impact of CTCL on patients’ HRQoL, and the treatment of pruritus.

show abstract

The Spectrum of Anaplastic Large‐cell Lymphoma

Kong

Feldman

2021

The Peripheral T‐Cell Lymphomas

View full text Add to dashboard Cite

Brentuximab a novel antibody therapy: real‐world use confirms efficacy and tolerability for CD30‐positive cutaneous lymphoma

Cited by 14 publications

References 7 publications

Poikilodermatous mycosis fungoides with CD30‐positive large cell transformation successfully treated by brentuximab vedotin

Poikilodermatous mycosis fungoides with CD30‐positive large cell transformation successfully treated by brentuximab vedotin

The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T‐cell lymphoma

The Spectrum of Anaplastic Large‐cell Lymphoma

Contact Info

Product

Resources

About